吡非尼酮：一种抗纤维化药物，在移植患者管理中具有潜在治疗作用。
Pirfenidone: anti-fibrotic agent with a potential therapeutic role in the management of transplantation patients.
作者信息
Dosanjh Amrita
机构信息
University of California-San Diego, School of Medicine, La Jolla, CA, USA.
出版信息
Eur J Pharmacol. 2006 May 1;536(3):219-22. doi: 10.1016/j.ejphar.2006.03.007. Epub 2006 Mar 14.
Pirfenidone has a simple chemical structure, but may have profound implications for transplantation management. One of the leading causes of allograft failure is chronic allograft dysfunction, manifested by chronic inflammation and chronic fibrosis [Estenne, M., Hertz, M.I., 2002. Bronchiolitis obliterans after human lung transplantation. AJRCCM. 166, 440-444.]. This review summarizes the literature to date on Pirfenidone in the setting of transplantation, and those studies pertinent to the mechanisms of organ rejection and possible use of Pirfenidone in transplantation patients.
吡非尼酮化学结构简单，但可能对移植管理产生深远影响。同种异体移植失败的主要原因之一是慢性同种异体移植功能障碍，表现为慢性炎症和慢性纤维化[埃斯泰内，M.，赫兹，M.I.，2002年。人类肺移植后的闭塞性细支气管炎。《美国呼吸与危重症医学杂志》。166，440 - 444]。本综述总结了迄今为止关于吡非尼酮在移植领域的文献，以及那些与器官排斥机制和吡非尼酮在移植患者中可能的应用相关的研究。
Zotero 插件